Goldman Sachs Group Inc Lyra Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 547,339 shares of LYRA stock, worth $103,994. This represents 0.0% of its overall portfolio holdings.
Number of Shares
547,339
Previous 24,391
2144.02%
Holding current value
$103,994
Previous $6,000
2266.67%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding LYRA
# of Institutions
62Shares Held
32.2MCall Options Held
21.1KPut Options Held
400-
Perceptive Advisors LLC New York, NY12.8MShares$2.42 Million0.09% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.77MShares$906,8350.0% of portfolio
-
Black Rock Inc. New York, NY2.83MShares$537,6950.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.78MShares$528,2490.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.78MShares$338,0590.0% of portfolio
About Lyra Therapeutics, Inc.
- Ticker LYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,826,400
- Market Cap $6.05M
- Description
- Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...